Toward a Molecular Classification of the Head and Neck Squamous Cell Carcinoma by Ceausu, Amalia Raluca et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Toward a Molecular Classification 
of the Head and Neck Squamous 
Cell Carcinoma
Amalia Raluca Ceausu, Eugen Radu Boia, Eugen Sorin Boia, 
Anca Maria Cimpean and Marius Raica
Abstract
The frequency of the squamous cell carcinoma of the head and neck is con-
stantly increasing, with over 550.000 new cases registered globally each year. The 
conventional histopathological diagnosis most commonly indicates the squamous 
cell carcinoma as tumor type and G2 as differentiation grade. Despite of this 
relative morphological uniformity, there is a great heterogeneity in the molecular 
profile, the therapeutic response and prognosis. Most probably, this entity includes 
many diseases, similar in basic morphologic features, but different in the biologi-
cal behavior. Trying to answer this question and to show discrepancies when they 
exist, we have evaluated in this book chapter, our own results and data from the 
literature in terms of molecular profile at the protein level, including the spectrum 
of proliferation markers, growth factors and their receptors, stromal proliferation, 
angiogenesis and lymphangiogenesis. These data will allow to identify some major 
criteria for a better stratification of cases, selected for gene analysis and personal-
ized therapy as a future perspective and direction.
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1. Introduction
The recent data regarding the global cancer statistic [1] indicate an increase 
number of new diagnosed HNSCC cases each year. Despite the efforts, the 5 years 
OS rate of HNSCC has not improve significantly over the last years. There are 
several reasons that can be mentioned: the classic causative factors such as alcohol 
consumption and tobacco usage, the presence of the lymph nodes metastases at 
the time of the diagnosis, important increase in the HPV infections in the Western 
world. [2]. Between 40 to 60% of HNSCC treated patients have recurrence and not 
respond to subsequent therapeutic interventions [3]. Another important reason 
may be the accentuated heterogeneity of HNSCC at the molecular level, the inabil-
ity of a clear stratification of the cases and the absence of a certain link between 
the molecular subtypes and the clinical outcome. A number between four and six 
molecular types of HNSCC were described in the literature. Chung [4] described 
four distinct subtypes: first (displays EGFR pathway and hypoxia related molecular 
signatures), the second is mesenchymal marker enriched, the third has features 
of normal epithelia and the fourth expresses high levels of transcripts coding for 
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antioxidant and detoxification enzymes. The four groups of HNSCC proposed 
by Walter [5] are: basal, mesenchymal, atypical, and classical. Five subgroups of 
HNSCC were described also by another research team: three HPV negative (basal, 
classical non- HPV and mesenchymal non -HPV) and two HPV positive (classical 
HPV and mesenchymal HPV) [6]. Other author described six subtypes (immuno-
reactive, inflammatory, HPV-like, classical, hypoxia associated and mesenchymal) 
[7]. The heterogeneity of the tumor microenvironment and the clear histological 
margin used today may be other reasons for tumor recurrences.
We try in the following to identify some major criteria for a better stratification 
of the cases, and for a better surveillance of the postoperative margins, targeting the 
personalized therapy.
2.  The conventional histopathological diagnostic and morphological 
features
The head and neck squamous cell carcinomas are epithelial tumors originating in 
the covering mucosa of oral cavity, larynx, oropharynx, and hypopharynx [8]. In an 
attempt to cover the heterogeneous spectrum of these tumors, the most used clinical 
management is based on anatomic location, phenotype, evaluation of the existence of 
tumor -node-metastasis by the TNM classification and the depth of tumor invasions 
[9]. The WHO classification of head and neck tumors includes tumors of the nasal 
cavity, paranasal sinuses and skull base (with the keratinizing, non-keratinizing and 
spindle cell squamous cell carcinoma types), tumors of the nasopharynx, of the hypo-
pharynx, larynx, trachea, parapharyngeal space (with the conventional, verrucous, 
basaloid, papillary, spindle cell types of squamous cell carcinomas), tumors of the oral 
cavity and mobile tongue, of the oropharynx (base of the tongue, tonsils, adenoids) 
with HPV positive and HPV negative types of squamous cell carcinoma, tumors and 
tumors-like lesions of the neck and lymph nodes, tumors of salivary glands, odonto-
genic and maxillofacial bone tumors, tumors of the ear and paraganglion tumors [10].
In the conventional histopathological diagnosis, the squamous cell carcinoma 
may be graded as well, moderate, and poorly differentiated type. The well dif-
ferentiated type of keratinized squamous cell carcinoma is characterized by the 
presence of the keratinizing and para-keratinizing pearls. Morphological features in 
the moderately differentiated squamous cell carcinoma are nuclear pleomorphism, 
mitoses, including atypical type and less keratinization. The poorly differentiated 
type is characterized by the predominance of the immature cells, a high number 
of typical and atypical mitoses, reduced keratinization and necrosis either over 
large areas of the section or in the center of the tumor areas, variable in extent. 
Most HNSCC are moderately- differentiated [11, 12] aspect sustained by our data 
where a percentage of 73.8% and 71% from HNSCC evaluated cases were diagnosed 
as G2 [13, 14]. The non-keratinized squamous cell carcinomas have the following 
morphological features: the existence of a large, interconnected band of tumor 
epithelial cells without keratinization and minimal or absent necrosis, pleomorphic 
cells, hyperchromasia and an intense mitotic activity.
The histologic grade prognostic impact remains controversial in HNSCC. It was 
accepted by the current edition of the Classification of Head and Neck Tumors but 
with the mention that grading alone does not correlate well with prognosis [15]. It 
is not a part of the UICC staging system, but some data consider high grade as an 
indication for the adjuvant treatment in OSCC [16, 17].
Starting from these premises it may be launched the question why the patients 
with the same histological grade have such a heterogeneous therapeutic response 
and prognosis.
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3.  The molecular profile at the protein level- cytokeratins, vimentin, 
podoplanin
The present molecular classification described four types of HNSCC as follow-
ing: classical, basal, mesenchymal, and atypical subgroups. Excepted from this are 
the hypopharyngeal cancers characterized by the absence of the BA subgroup.
Keratins are a family of the intermediate filament proteins which are present in 
epithelial cells. Some of the main functions of keratins are structural in forming 
the cytoskeleton, protein synthesis, cell growth, signaling, organelle transport, 
mobility, and cell proliferation [18]. The keratin pattern distribution in a stratified 
epithelium is as follows: K1, 2, 10 and 11 are positive in cornified cells, K4 and 13 in 
stratified cells and K5 and 14 in basal cells [19].
The aberrant expression of keratins was found to be associated with HNSCC 
development and progression. High values of K 8, 17 and 19 immunoexpression were 
noticed in the biopsies of head and neck squamous cell carcinoma patients [20].
Keratin 5 was showed to be expressed with value of score between 1 and 
3 (more than 30% positive cells), in squamous cell carcinoma with different 
histological grade and anatomical localization [21]. K5 together with EGFR, p63, 
CD 117 may be a helpful marker for define a distinct class of HNSCC (basal -like 
type, characterized by K5+/EGFR +/p63+/CD117+ profile). On the other hand, 
keratin 5 expression has been shown to correlate with the intermediate phenotype 
of cells involved in the epithelial-mesenchymal transition phenomenon [13, 22]. 
Some data demonstrated the by the immunohistochemical evaluation a loss of 
epithelial markers such as keratin 76 and epithelial cell adhesion molecule in the 
HNSCC [23, 24]. E- cadherin, involved in the cancer progression and metastasis 
by decrease of cellular adhesion and increase in cellular motility is co-expressed 
with Ep CAM. A decrease of E-cadherin expression associated with HPV 18 
positivity were found in well and moderately differentiated type of HNSCC 
with larynx, oropharynx, pharyngo- laryngeal, and nasal-sinus localization. 
The rhino-pharynx, hypo-pharyngeal and laryngeal HPV18 negative cases were 
associated with a decrease of E-cadherin values in the moderately, poorly, and 
undifferentiated types.
The demonstrated role of cytokeratins in the diagnosis and prognosis of squa-
mous cell carcinomas by using surrogate markers and biopsy tissues, oriented the 
research in the direction of a non-invasive diagnostic biomarker such as salivary 
keratins for the HNSCC [14, 19, 25].
The other molecule expressed in the basal cells of stratified epithelium is K14 
which has an important role in cell differentiation. It was shown that K14 downreg-
ulation is associated with an increase in TAp63 and Notch-1 intracellular expression 
which regulates genes responsible for differentiation [26].
Vimentin is an intermediate filament intensely expressed in cells with mes-
enchymal phenotype. Its expression in oral epithelial cells has been linked by the 
tumor invasion, metastasis and EMT phenomenon [27].
It was shown that miR-876-5p, a tumor suppressor in HNSCC, represent a novel 
therapeutic target by acting on vimentin and inhibits metastasis [28].
The potential prognostic role of vimentin was described for TSCC and OSCC 
[29, 30]. In the first situation, vimentin among the EMT related proteins such as 
Snail, E- cadherin and N-cadherin are involved. In the second situation, an asso-
ciation between vimentin intense immunoexpression and a high risk for cervical 
lymph node metastatic potential was noticed. It was showed that vimentin-SOX 
2 interrelation may represent an unfavorable risk factor for survival of head and 
neck squamous cell carcinoma. The loss of SOX2 expression induces cell motility by 
vimentin up-regulation [31].
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Podoplanin, a 38 KDa type I transmembrane glycoprotein is overexpressed in 
different human cancers, including HNSCC.
An interrelation between histological grade differentiation and podoplanin 
immunoexpression was described in HNSCC. The main pattern of immunoex-
pression was in the cytoplasm and membrane with focal (mainly in the well dif-
ferentiated OSCC) and diffuse distribution type (mainly in the moderately and 
poorly differentiated OSCC). The podoplanin was not expressed in the some of the 
well and poorly differentiated oral SCC cases. In all the moderately differentiated 
cases of SCC a positive reaction for podoplanin was noticed. The highest values 
for podoplanin with cytoplasm and membrane pattern expression was associated 
with poorly differentiated of oral SCC type. High levels of podoplanin expression 
was associated with high frequency of lymph node metastasis in OSCC [32]. A 
tendency of increasing podoplanin expression with decreasing of differentiation 
grade was noticed [33]. In OSCC was demonstrated the podoplanin involvement 
in the cytoskeleton remodeling, ECM degradation and tumor invasion. These are 
realized by co-location, co-ordination of podoplanin, Cdc42 and MT1-MMP in the 
invadopodia [34].
SCCs of the larynx and hypopharynx with high values of podoplanin expression 
were associated with an unfavorable prognosis also [35]. Podoplanin may have a 
predictive value of aggressiveness in HNSCC evolution, together with other markers 
such as EGFR and E-cadherin.
Another pathway through which podoplanin induces a decrease in overall survival 
was shown in the murine experimental models. Podoplanin expression in the OSCC 
tumors increased platelet activation and promotes intravascular platelet aggregation 
and intratumor platelet infiltration. The coagulation state is favorized [36].
4. Proliferation markers: p53 and Bcl2
P53 is a transcription factor that regulates the cell cycle, DNA repair and 
apoptosis. One of its main role is to maintain cellular integrity after DNA damage. 
Consecutive to this moment, p53 is regulated in a MDM2-dependent manner and 
activated by cell cycle checkpoint kinases type 1 and 2 [37]. In normal conditions, 
p53 may be expressed with a nuclear pattern in basal cells of the epithelium. In 
HNSCC p53 immunoexpression was described in 50% of the evaluated cases or 
more. Controversial data concerning p53/EGFR co-expression exists. In our data, 
44% of larynx and 70.5% of pharynx cases co-expressed p53/ EGFR. All of the p53 
positive cases co-expressed EGFR. These features were noticed by using a double 
immunohistochemical staining p 53/ EGFR. For larynx localization, p53/ EGFR 
co-expression was noticed mainly at the periphery of the tumor area (in all of the 
moderately differentiate cases- Figure 1, in 25% of well differentiate cases with 
much more reduced number of co-expressing cells, in 50% of poorly differentiated 
type). In corresponding lymph nodes of laryngeal tumors, the co-expressing cells 
were present in the immediate vicinity of the lymphoid tissue and to the periphery 
of tumor areas. In the center of tumor areas EGFR or p53 positive cells only were 
found, not co-expressing cells. The distribution pattern of the co-expressing cells 
from the hypopharynx may be noticed in the Figure 2. The distribution pattern of 
co-expressing cells to the periphery of tumor areas was found in the oropharynx, 
pharyngo-laryngeal and sinus nose localization. The co-expressing cells were absent 
in the naso-pharyngeal localization. A significant correlation was found between 
p53 intensity of expression and extranodal extension and tumor grade, mainly 
grades II and III [38, 39]. All of these p53/EGFR co-expression data may be useful 
for a better stratification of HNSCC, regarding the diagnostic but the therapy also.
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The major pathways involved in the tumorigenesis of HNSCC include dysregu-
lation of the following processes: cellular survival and proliferation, cell-cycle 
control, cellular differentiation and adhesion and invasion signaling. The main 
important factors involved in the cellular survival and proliferation are: TP53, 
HRAS, EGFR, PIK3CA. The functional inactivation of the p53 pathway was dem-
onstrated in 80% of HNSCC, that why a therapeutic strategy which focus on the 
restoration of p53 function was developed for the HPV negative and HPV associ-
ated HNSCC. Unfortunately, the adenoviral p53 gene therapy has not been shown to 
be effective in clinical trials [40, 41].
Figure 1. 
p53/EGFR co- expression (white arrows) in tumor area in a case of moderately differentiated squamous cell 
carcinoma with larynx localization, double immunostaining p53/EGFR, ob.X40.
Figure 2. 
EGFR/p53 immunoexpression, non-keratinized squamous cell carcinoma, moderately differentiated of 
hypopharynx, double immunostaining p53/EGFR, ob.X40.
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Another important role of p 53 is the expression in the surgical margins. 
Pathology in the margin represent an considerable prognostic factor for relapse free 
survival (RFS) in the management of HNSCC treated with primary surgery. In the 
OSCC, a local recurrence value varies between 10 and 30% even if the histological 
status of margins is clear. The following surgical margins classification is used by 
surgeons and pathologists: involved margins (margin ≤1 mm), close margins (mar-
gin 1–5 mm) and clear margins (margin >5 mm) [42]. Severe dysplasia and invasive 
carcinoma needing additional resection while moderate and mild dysplasia do not. 
Evaluation of the p53 overexpression in histological resection margins of oral and 
oropharyngeal SCC demonstrated a 5.333 times higher chance of local recurrences 
if at least one margin overexpressed p53. P53 as an independent risk factor has been 
demonstrated in early OSCC with dysplastic surgical margin. It may be a useful 
marker for postoperative decision for these patients [43, 44].
Bcl-2 (B-cell lymphoma 2) encoded in humans by the Bcl2 gene is a member 
of the family of regulatory proteins that influence apoptosis through both pro and 
anti-apoptotic or inhibitory effects. Pro-survival Bcl-2 proteins (Bcl-2, Bcl-xL, 
MCL-1) inhibit Bcl-2 pro-apoptotic effectors (BAX and BAK).
The immunohistochemical evaluation of cases from our studies, revealed a 
relatively reduce number of bcl2 cases. The value of positive cases was close to 30%. 
The differences were noticed between anatomic areas. At the larynx, oropharynx, 
hypopharynx, nasopharynx, bcl 2expression in some of the cases was found. At the 
pharingo-larynx, nasal sinus, bcl2 expression was absent. Cases of well and poorly 
differentiated keratinized squamous cell carcinoma of the larynx were character-
ized by the absence of Bcl2 immunohistochemical expression in tumor cells. A 
similar appearance was noticed in the tumor cells of the corresponding lymph 
node. The Bcl2 immunoexpression had a score value 2 (10–30% positive tumor 
cells) in primary tumor and corresponding lymph node of the squamous keratin-
ized moderately differentiated larynx carcinoma. The same value was found in the 
oropharynx. In the lymph node of the non-keratinized moderately differentiated 
type of the larynx squamous cell carcinoma more than 50% of bcl 2 positive tumor 
cells were noticed (a value 3 of the score).
In the hypopharynx localization isolated Bcl 2 positive tumor cells were found in the 
tumor areas (score value 1, with less than 10% Bcl2 positive tumor cells- Figure 3). An 
intense Bcl2 expression as intensity and value of the score was expressed in the stromal 
cells in the vicinity of tumor areas.
The highest value score of Bcl2 (value 3: more than 50% Bcl2 positive tumor 
cells- Figure 4) was present in the non-keratinized moderately differentiated 
squamous cell carcinoma with rhino-pharynx localization. In the group of EGFR 
positive cases, 3 sub groups were described: EGFR+/p53−/bcl2-, EGFR+/p53+/bcl2+ 
and EGFR+/p53+/bcl2−/with a significant correlation between N parameter and 
EGFR expression in this last subgroup. In the K5+/EGFR + cases significant correla-
tion between bcl2 and M (p = 0.01) and N (p = 0.04) parameters were found. Other 
HNSCC immunohistochemistry data indicated a higher Bcl 2 expression, compare 
with our data, around 88% of evaluated cases. A significant correlation was 
reported between the Bcl2 expression and histological grade, lymph node involve-
ment but not clinical stage. They noticed a significant association between p53+/
Bcl2 + and histological grade, lymph node involvement [13, 45].
Other authors considered that immunohistochemical staining of Bcl2 is not 
significantly correlated with tumoral aggressiveness and prognosis to the patients 
diagnosed with laryngeal squamous cell carcinoma and treated with primary 
surgery [46]. The molecular mechanism and genetic basis of the development of 
larynx carcinoma have not been fully elucidated. Some data revealed the involve-
ment of Bcl2-Hsp90beta in the anti-apoptotic progression of larynx carcinoma. The 
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disruption of Bcl2-Hsp90beta interaction inhibited the anti-apoptotic ability of Bcl2 
and reduced the capsize activation in larynx carcinomas [47].
It was demonstrated the role of miR-15a as a suppressor in HPV positive by 
targeting bcl2 in HSCC [48]. The effect of Navitoclax (a small inhibitor molecule 
Figure 3. 
Value 1 of Bcl2 immunoexpression score inside the tumor area (white arrows), in a moderately differentiated 
squamous cell carcinoma of the hypopharynx, Bcl2 immunostaining, ob.X40.
Figure 4. 
Value 3 of Bcl-2 expression score in a moderately differentiated, non-keratinized squamous cell carcinoma of 
the rhinopharynx, Bcl2 immunostaining, ob. X 20.
Surgical Management of Head and Neck Pathologies
8
of Bcl-2/Bcl-xL), in high doses was the death of HNSCC cells. But a limited effect 
was found in combination with radiation or cisplatin. Co-inhibition of MCL-1 was 
required to improve approaches targeting Bcl-2/Bcl-xL in HNSCC. [49]
By evaluate two groups of metastatic and non-metastatic primary OSCC, 
Pavithra et al. [50] found no significant difference in the expression of Bcl2 between 
the two groups. They sustained that evaluation of Bcl2 along with other apoptotic 
proteins could define the role in prognosis and pathogenesis of OSCC.
Taking into account all these data, bcl2 alone or together with p53 expression 
may still represent some important markers for tumor agressivity and survival rates 
in the conditions of a better stratification of the patients.
5. Growth factors and their receptors
Some of the most important growth factors already described to be involved in 
the prognosis or therapy resistance of HNSCC are: epidermal growth factor (EGF) 
and it receptor EGFR, vascular endotelial growth factor (VEGF) and VEGFR 1 
and 2 mainly, platelet derived growth factor (PDGF AA) and PDGFR alpha, nerve 
growth factor (NGF) and transforming growth factor beta (TGF-beta).
There are some molecular-targeted therapies used in the treatment of head and 
neck squamous cell carcinoma. The molecular targeted therapy such as Cetuximab, 
panitumumab, zalutumumab and nimotuzumab acts on EGFR monoclonal anti-
bodies; Gefitinib, erlotinib, lapatinib, afatinib, dacomitinib inhibit EGFR tirosin 
kinase receptors; Bevacizumab (VEGF inhibitor); Sorafenib, sunitinib, vandetanib 
(VEGFR inhibitors); Rapamycin, temsirolimus, everolimus, torin 1, PP242 and 
PP30 (PI3K/AKT/mTOR pathway); Pembrolizumab and nivolumab (anti-PD-1).
The EGFR ligands such as EGF, transforming growth factor alpha (TGFA), 
heparin-binding EGF-like growth factor (HBEGF), amphiregulin (AREG), beta-
cellulin (BTC), epiregulin (EREG) and epigen (EPGN) are involved in tumor 
growth, invasion and metastatic process through EGFR activation. In HNSCC, 
these ligands/receptors are deregulated. It was noticed an important correlation 
between mRNA levels of four EGFR ligands and the poor prognosis in HNSCC. The 
inhibiting EGF- induced AREG expression was proposed as a new treatment option 
in HNSCC [51].
The EGFR targeting monoclonal antibody, Cetuximab was FDA approved for 
HNSCC treatment in 2006. But, despite the advances in therapy, the overall five 
years survival rate of patients with advanced HNSCC remains relatively reduced, 
around 40–50%. Some data described mutations in various oncogenes and tumor 
suppressor genes in HNSCC profile, as following: PIK3CA (21%), HRAS (4%), 
TP53 (72%), CDKN (22%), FBXW7 (5%), KMT2D (MLL2) (18%) and PTEN 
(2%). PI3K/AKT pathway responsible of proliferation, survive and cell differentia-
tion exhibit alterations in around 34% of patients diagnosed with HNSCC. This 
pathway may be responsible for tumor escape during EGFR targeting in HNSCC. It 
was demonstrated the role of PIK3CA and RAS mutations in predicted cetuximab 
resistance in the first line recurrent and/or metastatic setting and the role of PTEN 
protein expression loss in predicted resistance to cetuximab when combined to 
radiotherapy [52].
VEGF- A and the others family members (VEGF-B, VEGF-C, VEGF-D) are 
overexpressed in the majority of HNSCC cases. They act by inducing tumor growth 
by changing the microvascular density, favorizing cell migration and metastasis. 
The reduced sensitivity to radiation and progression of HNSCC is associated with 
stimulation of angiogenesis by tumor cells that undergo radiotherapy. The results of 
phase I and II clinical trials of Bevacizumab and erlotinib combined administration 
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indicated an increase of median survival by seven months. One of the therapeutic 
agents, which induce autophagy and inhibits tumor growth was Sorafenib, a serine- 
threonine protein kinase inhibitor b-Raf, C-Raf, VEGF and PDGFR. Sunitinib, a 
small molecule kinase inhibitor of VEGFR, PDGFR and c-kit tyrosine kinase has a 
reduced effect if it is use as monotherapy but associated with Cetuximab favorized 
the decrease of tumor cell proliferation and an increase of cell differentiation. 
Vandetanib, which targeted on EGFR, VEGFR2, RTK used in combination with 
cisplatin and radiotherapy reduced the resistance to EGFR inhibitors in preclinical 
trials [53]. It was demonstrated also the role of the preoperative or postopera-
tive serum levels of VEGF as a predictive factor for recurrence, disease- free and 
overall survival of patients with HNSCC [54]. The results obtained on culture cells 
support the application in clinical practice of the levels of the VEGFR promoters. 
Methylation of VEGFR1 and VEGFR3 promoters correlated with poor prognosis. 
It was established a link between methylation of the VEGFR2 promoter and lymph 
node metastasis [55].
Concerning PDGF and their receptor it was found a prognostic role of PDGF 
serum level in patients with OSCC and a worse prognostic of HNSCC patients induced 
by the presence of PDGFR-alfa expression in the tumor microenvironment [56, 57].
Both normal and malignant epithelial cells expressed NGF receptors and NGF 
gene. Neurotrophins are involved in perineural growth in HNSCC, a pathway of 
tumor progression associated with poor prognosis. Neurotrophins link to low 
affinity nerve growth factor (LNGFR/p75 neurotrophin receptor-p75 NTR) or to 
the high affinity Trk (tropomyosin related kinase) tyrosine kinase receptors. P75 
NTR was described in an undifferentiated cell population of oral leukoplakia and 
in OSCC where was associate with a poor prognosis. P75NTR contribute to drug 
resistance, by involvement in multiple signaling pathways. A correlation between 
neurotrophin receptor tyrosine kinase (NTRK2) overexpression and epithelial to 
mesenchymal transition in HNSCC tumor cells was found. It seems that p75NTR 
might related with NGF -independent therapy resistance in HNSCC, while NTRK1 
might transduce a survival signal on NGF and improved cell survival after cell cycle 
arrest [58].
Another important growth factor with increased importance in HNSCC is hepa-
tocyte growth factor (HGF) and its receptor c-MET. The overexpression of HGF 
was commonly reported in HNSCC cases. C-MET was overexpressed in lymph node 
metastasis of HNSCC. C-MET encodes mesenchymal epithelial transition factor which 
favorized invasion and metastatic potential in cancers. Their overexpression may be 
associated with worse prognostic and reduced overall survival rate. EGFR and c-MET 
share common downstream pathways: RAS-RAF-MAPK and PI3K-AKT-mTOR. In the 
patients with resistance to EGFR targeted therapies c-MET/HGF inhibitors may repre-
sent an alternative solution. Capmatinib as monotherapy and Ficlatuzumab combined 
with Cetuximab are some of c-MET/HGF axis therapeutic solutions.
Transforming growth factor beta realized homeostasis between the proliferation 
and apoptosis of normal epithelial cell by Smads or Smad independent downstream 
pathways. Tumor suppression and tumor promotion is the main role of TGF beta in 
HNSCC [59].
6.  The afferent stroma proliferation. The mast cell, blood vessels and 
lymphatic vessels involvement
The stromal component of the tumor microenvironment contains different cells 
types such as: cancer associated fibroblast, macrophages, regulatory T cells and 
mast cells.
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Regulatory T cells recruitment is regulated by chemokines and associated recep-
tors (CCL28-CCR10 and CXCL12-CXCR4). The immunohistochemical specific 
markers of these cells are CD4 and CD25. It was identified a subgroup of Tregs, 
TIM3, with high levels of T-cell immunoglobulin and mucin domain-3. It was notice 
that these cells are linked with resistance to radiotherapy and their number decrease 
after PD-1 monoclonal antibody administration. In HNSCC, a high number of Tregs 
induces a negative prognostic [60].
Described for the first time by Ehrlich in 1878, mast cells differ through their 
localization and content, depending on their phenotype: connective tissue MCs and 
mucosal MCs. Mast cells granules contained preformed mediators such as: trypt-
ase, chymase, cathepsin G, histamine, heparin, serotonin, IL-16, and TNF alpha. 
Mediators synthesized after mast cell activation are interleukines (IL1, IL 3, IL4, IL 
5, IL6, IL 8, IL 10, IL 13, IL 16, platelet activating factor, RANTES, MIF 1 alpha) and 
arachidonic acid metabolites, prostaglandin and leukotriene C4 [61, 62].
In HNSCC, some authors noticed a decrease in mast cell number associated with 
advanced histological grade in OSCC, other found a significant correlation between 
mast cells density and G1, G2 histological grade in larynx carcinoma [63, 64].
By the content of their granules such as VEGF or other substances with angio-
genic properties, mast cells may stimulate angiogenesis. In the larynx carcinoma, 
the differentiation grade was correlated with mast cell density but not with the 
microvascular density [64]. Other data indicated a higher MVD in HNSCC compare 
with MVD values noticed in dysplasia of the upper respiratory tract epithelium. No 
significant correlation was found between MVD/CD34 values and local invasive-
ness (the T feature) in HNSCC [65]. Increased values of MVD and mast cell density 
were present in OSCC compare with leukoplakia with and without dysplasia. [66]
Lymphangiogenesis is the process of new lymphatic vessel formation. The 
growth factors such as VEGF-C, VEGF -D, PDGF-BB and HGF may influence the 
formation of new lymphatic vessels. Both lymphatic and microvascular density in 
peritumoral area may have a prognostic value. Some data demonstrated that peritu-
moral MVD was associated with metastasis and LMVD was inversely related to both 
metastasis and progression in HNSCC [67]. Other authors compared the intra and 
peritumoral lymphatic microvascular density and found a significantly lower den-
sity in the peri-tumoral areas. They found significant correlation between LMVD 
values (intra and peri-tumoral) and differentiation degree. From clinical param-
eters, an important correlation between total LMVD and lymph node status, but 
not tumor stage was reported [68]. These observations were reconfirmed by other 
study which reported an important correlation between both high intra-tumoral 
and peritumoral LVD and lymph node metastasis. The morphology of peri-tumoral 
lymphatic vessels was similar, with a large lumen, like in the previously study, but 
the number of lymphatic vessels was higher in peritumoral area compared with 
intra-tumoral area, opposite to previous study [69].
These results support the importance of the lymphangiogenesis and lymphatic 
vascular density as risk and prognostic factors of the patients with lymph node 
metastasis.
7. Conclusions
From the mentioned data results the necessity of a better stratification of 
HNSCC. The novel molecular techniques of the surgical margins can offer a more 
accurate risk assessment. The results of genetic and molecular biology studies may 
outline the criteria for the targeted therapy as a fundamental method of cancer 
treatment in the future.
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